These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19730283)

  • 1. Management of HIV in resource limited settings.
    McCutchan JA
    Curr Opin Infect Dis; 2009 Oct; 22(5):464-70. PubMed ID: 19730283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings.
    Bartlett JA; Hornberger J; Shewade A; Bhor M; Rajagopalan R
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(4):253-68. PubMed ID: 19721103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.
    Quentin W; König HH; Schmidt JO; Kalk A
    Trop Med Int Health; 2008 Oct; 13(10):1245-56. PubMed ID: 18721185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing opportunistic infections in human immunodeficiency virus-infected persons: implications for the developing world.
    Kaplan JE; Hu DJ; Holmes KK; Jaffe HW; Masur H; De Cock KM
    Am J Trop Med Hyg; 1996 Jul; 55(1):1-11. PubMed ID: 8702012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMMENTARY: understanding the benefits of pediatric anti-retroviral treatment in resource-limited settings.
    Hetherington S
    Pediatr Infect Dis J; 2009 Jan; 28(1):41-2. PubMed ID: 19057455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies to optimize HIV treatment outcomes in resource-limited settings.
    Nakanjako D; Colebunders R; Coutinho AG; Kamya MR
    AIDS Rev; 2009; 11(4):179-89. PubMed ID: 19940945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy.
    O'Brien DP; Sauvageot D; Zachariah R; Humblet P;
    AIDS; 2006 Oct; 20(15):1955-60. PubMed ID: 16988517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.
    Jordan MR; Bennett DE; Bertagnolio S; Gilks CF; Sutherland D
    Antivir Ther; 2008; 13 Suppl 2():15-23. PubMed ID: 18575188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The obligation to provide antiretroviral treatment in HIV prevention trials.
    Lo B; Padian N; Barnes M
    AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
    Bishai D; Colchero A; Durack DT
    AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings.
    Schneider K; Puthanakit T; Kerr S; Law MG; Cooper DA; Donovan B; Phanuphak N; Sirisanthana V; Ananworanich J; Ohata J; Wilson DP
    AIDS; 2011 Jun; 25(9):1143-51. PubMed ID: 21505319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of antiretroviral failure and resistance in developing countries.
    Hawkins C; Murphy RL
    Curr Opin HIV AIDS; 2009 Nov; 4(6):538-44. PubMed ID: 20048723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuro OIs: developed and developing countries.
    Wright EJ
    Curr Opin HIV AIDS; 2014 Nov; 9(6):539-44. PubMed ID: 25250554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Socioeconomic aspects of human immunodeficiency virus (HIV) infection in developing countries].
    Gentilini M; Chieze F
    Bull Acad Natl Med; 1990 Nov; 174(8):1209-19; discussion 1219-21. PubMed ID: 2094555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in antiretroviral therapy.
    Wilkin TJ; Shalev N; Tieu HV; Hammer SM
    Top HIV Med; 2010; 18(2):66-92. PubMed ID: 20516526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finding patients eligible for antiretroviral therapy using TB services as entry point for HIV treatment.
    Bwire R; Nagelkerke NJ; Borgdorff MW
    Trop Med Int Health; 2006 Oct; 11(10):1567-75. PubMed ID: 17002731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges.
    Vitoria M; Vella S; Ford N
    Curr Opin HIV AIDS; 2013 Jan; 8(1):12-8. PubMed ID: 23188179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Access to antiretroviral treatment in developing countries: Which financing strategies are possible?
    Beaulière A; Le Maux A; Trehin C; Perez F
    Rev Epidemiol Sante Publique; 2010 Jun; 58(3):171-9. PubMed ID: 20430553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Brazilian experiment: HIV drugs for all.
    Flaer PJ; Younis MZ
    J Health Care Finance; 2009; 36(2):90-6. PubMed ID: 20499725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
    Pinheiro Edos S; Antunes OA; Fortunak JM
    Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.